Hosford, S. R., Dillon, L. M., Bouley, S. J., Rosati, R., Yang, W., Chen, V. S., . . . Miller, T. W. (2016). Combined inhibition of both p110α and p110β isoforms of phosphatidylinositol 3-kinase is required for sustained therapeutic effect in PTEN-deficient, ER+ breast cancer. Clin Cancer Res.

Hosford, Sarah R., Lloye M. Dillon, Stephanie J. Bouley, Rachele Rosati, Wei Yang, Vivian S. Chen, Eugene Demidenko, Rocco P. Morra, und Todd W. Miller. "Combined Inhibition of Both P110α and P110β Isoforms of Phosphatidylinositol 3-kinase Is Required for Sustained Therapeutic Effect in PTEN-deficient, ER+ Breast Cancer." Clin Cancer Res 2016.

Hosford, Sarah R., et al. "Combined Inhibition of Both P110α and P110β Isoforms of Phosphatidylinositol 3-kinase Is Required for Sustained Therapeutic Effect in PTEN-deficient, ER+ Breast Cancer." Clin Cancer Res 2016.